{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:46:18Z","timestamp":1786625178181,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Lutetium-177-Dotatate (Lutathera<jats:sup>\u00ae<\/jats:sup>) is a combined radionuclide-peptide that is FDA-approved for the treatment of well-differentiated, somatostatin receptor-positive, gastroenteropancreatic neuroendocrine tumors. Carcinoid crisis is a rare, but potentially life-threatening risk of this radiopharmaceutical, of which prompt recognition and treatment is essential to reducing morbidity. This manuscript provides an overview of the topic to promote awareness of this adverse event, with emphasis on early recognition and management. In addition, we present our institution\u2019s experience with Lutetium-177-Dotatate-associated complications across a five-year period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A literature review of lutetium-177-dotatate therapy and its potential implication of carcinoid crisis was performed. Additionally, a review of our institution\u2019s experience is presented.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The incidence of carcinoid crisis induced by Lutetium-177-Dotatate therapy is estimated to range between 1 and 2% of treatment recipients. Those who have tumors located within the midgut, higher tumor burden, and the presence of metastasis have an increased risk of developing carcinoid crisis, among other risk factors. Carcinoid crisis is most often encountered within 12\u201348\u00a0h of receiving the first treatment dose, with the most common symptoms being nausea\/vomiting, flushing, and diarrhea.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Carcinoid crisis is a rare but potentially life-threatening complication of Lutetium-177-Dotatate therapy. Knowledge of risk factors and prompt recognition of symptoms is essential to successful treatment, with early initiation of intravenous octreotide serving a critical step in reducing morbidity of this adverse event.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41824-024-00216-6","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T23:03:37Z","timestamp":1726182217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Carcinoid crisis in Lutetium-177-Dotatate therapy of neuroendocrine tumors: an overview of pathophysiology, risk factors, recognition, and treatment"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3641-135X","authenticated-orcid":false,"given":"Stephen J.","family":"Sozio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Raynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Yudd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"issue":"3","key":"216_CR17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3390\/cancers14030662","volume":"14","author":"C Baradasi","year":"2022","unstructured":"Baradasi C, Benatti S, Luppi G, Garajova I, Piacentini F, Dominici M, Gelsomino F (2022) Carcinoid Crisis: a misunderstood and unrecognized Oncological Emergency. Cancers 14(3):662","journal-title":"Cancers"},{"issue":"2","key":"216_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1148\/radiol.2020201745","volume":"298","author":"BJ Burkett","year":"2020","unstructured":"Burkett BJ, Dundar A, Young JR et al (2020) How we do it: a Multidisciplinary Approach to 177Lu DOTATATE peptide receptor Radionuclide Therapy. Radiol 298(2):261\u2013274","journal-title":"Radiol"},{"issue":"6","key":"216_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/oncolo\/oyad057","volume":"28","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Anthony L, Delcher C, Moga DC, Chauhan A, Huang B, Adams V (2023) Prescribing characteristics of Octreotide Immediate-Release and Long-Acting Release in patients with neuroendocrine tumors. Oncologist 28(6):479\u2013485","journal-title":"Oncologist"},{"key":"216_CR10","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/jcp.30062","volume":"236","author":"E Costanzi","year":"2021","unstructured":"Costanzi E, Simioni C, Conti I, Laface I, Varano G, Brenna C, Neri LM (2021) Two neuroendocrine G protein-coupled receptor molecules, somatostatin and melatonin: physiology of Signal Transduction and therapeutic perspectives. J Cell Physiol 236:2505\u20132518","journal-title":"J Cell Physiol"},{"issue":"10","key":"216_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3(10):1335\u20131342","journal-title":"JAMA Oncol"},{"key":"216_CR12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00259-007-0691-z","volume":"35","author":"B de Keizer","year":"2008","unstructured":"de Keizer B, van Aken MO, Feelders RA et al (2008) Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging 35:749\u2013755","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"216_CR15","doi-asserted-by":"crossref","unstructured":"del Olmo-Garcia MI, Muros MA, Lopez-de-la-Torre M et al (2020) Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine tumors. A systematic review and Approach proposal. J Clin Med, ; 9(7)","DOI":"10.3390\/jcm9072203"},{"key":"216_CR16","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jcrc.2020.08.011","volume":"60","author":"J Dhanani","year":"2020","unstructured":"Dhanani J, Pattison DA, Burge M et al (2020) Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): a case report. J Crit Care 60:318\u2013322","journal-title":"J Crit Care"},{"issue":"3","key":"216_CR13","first-page":"e7186","volume":"12","author":"AK Gade","year":"2020","unstructured":"Gade AK, Olariu E, Douthit NT (2020) Carcinoid syndrome: a review. Cureus 12(3):e7186","journal-title":"Cureus"},{"issue":"7","key":"216_CR11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/MPA.0000000000001597","volume":"49","author":"TR Halfdanarson","year":"2020","unstructured":"Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O\u2019Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA (2020) The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of pancreatic neuroendocrine tumors. Pancreas 49(7):863\u2013881","journal-title":"Pancreas"},{"issue":"3","key":"216_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis C, Kaltsas G, Davies P (2017) ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues. Neuroendocrinology 105(3):295\u2013309","journal-title":"Neuroendocrinology"},{"key":"216_CR9","doi-asserted-by":"crossref","unstructured":"Hofman MS, Lau WFE, Hicks RJ (2015) Somatostatin Receptor Imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in Interpretation. Radiographics, ; 35(2)","DOI":"10.1148\/rg.352140164"},{"issue":"4","key":"216_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.prro.2022.02.002","volume":"12","author":"AY Jia","year":"2022","unstructured":"Jia AY, Kashani R, Zaorsky NG et al (2022) Lutetium-177 DOTATATE: a practical review. Practl Radiat Oncol 12(4):305\u2013311","journal-title":"Practl Radiat Oncol"},{"issue":"2","key":"216_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2214\/AJR.19.21123","volume":"213","author":"A Kendi","year":"2019","unstructured":"Kendi A, Tuba TR, Halfdanarson AP et al (2019) Therapy with 177Lu-DOTATATE: clinical implementation and impact on care of patients with neuroendocrine tumors. Am J Roentg 213(2):309\u2013317","journal-title":"Am J Roentg"},{"issue":"6","key":"216_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/COC.0000000000000903","volume":"45","author":"C Love","year":"2022","unstructured":"Love C, Desai NB, Abraham T et al (2022) ACR-ACNM-ASTRO-SNMMI practice parameter for Lutetium-177 (Lu-177) DOTATATE therapy. Am J Clin Oncol 45(6):233\u2013242","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"216_CR18","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2214\/AJR.18.19953","volume":"211","author":"E Mittra","year":"2018","unstructured":"Mittra E (2018) Neuroendocrine tumor therapy: 177Lu-DOTATATE. AJR Am J Roentgenol 211(2):278\u2013285","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"216_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","volume":"9","author":"IM Modlin","year":"2008","unstructured":"Modlin IM, Kjell Oberg DC, Jensen R et al (2008) Gastroenterohepatic Neuroendocrine Tumors Lancet Oncol 9(1):61\u201372","journal-title":"Gastroenterohepatic Neuroendocrine Tumors Lancet Oncol"},{"issue":"1","key":"216_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nrendo.2011.120","volume":"8","author":"G Rindi","year":"2012","unstructured":"Rindi G, Wiedenmann G (2012) Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Reviews Endocrinol 8(1):54\u201364","journal-title":"Nat Reviews Endocrinol"},{"issue":"3","key":"216_CR7","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3390\/ijms23031447","volume":"23","author":"O Rogoza","year":"2022","unstructured":"Rogoza O, Megnis K, Kudrjavceva M et al (2022) Role of somatostatin signaling in neuroendocrine tumours. Int J Mol Sci 23(3):1447","journal-title":"Int J Mol Sci"},{"key":"216_CR22","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1007\/s00259-007-0457-7","volume":"34","author":"EJ Rolleman","year":"2007","unstructured":"Rolleman EJ, Kooij PP, de Herder WW, Valkema R, Krenning EP, de Jong M (2007) Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. Eur J Nuc Med Mol Imag 34:1854\u20131860","journal-title":"Eur J Nuc Med Mol Imag"},{"issue":"2","key":"216_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2018","unstructured":"Strosberg J, El-Haddad G, Wolin E et al (2018) Phase 3 trial of 177Lu-Dotatate for Midgut neuroendocrine tumors. N Eng J Med 376(2):125\u2013135","journal-title":"N Eng J Med"},{"key":"216_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.03.002","volume":"66","author":"G Tapia Rico","year":"2018","unstructured":"Tapia Rico G, Li M, Pavlakis N, Cehic G, Price TJ (2018) Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): literature review and case series from two Australian tertiary medical institutions. Cancer Treat Rev 66:1\u20136","journal-title":"Cancer Treat Rev"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-024-00216-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-024-00216-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-024-00216-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T23:04:09Z","timestamp":1726182249000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhi.springeropen.com\/articles\/10.1186\/s41824-024-00216-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["216"],"URL":"https:\/\/doi.org\/10.1186\/s41824-024-00216-6","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a systematic review which does not include any identifiable protected health information. Thus, no ethical approval or consent is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}